Epalrestat, aldose reductase inhibitor

Development of (Z, )-5-(2-methyl-3-phenyl-2-propenylidene)4-oxo-2-thio-xothiazolidine-3-acetic acid (Epalrestat, Kinedak), an aldose reductase inhibitor 97YGK651. 

Aldose reductase inhibitors (SEDA-19, 397 SEDA-20, 399 SEDA-21, 447 SEDA-22, 477) have been developed for the treatment of secondary complications in diabetes (1,2). They include alrestatin, benurestat, epalrestat, fidarestat, imirestat, lidorestat, minalrestat, ponalrestat, ranirestat, risarestat, sorbinil, tolrestat, zenarestat, and zopolrestat (all rINNs). 

Oral antidiabetics Aldose reductase inhibitors Epalrestat... 

---